Ipsogen Announces 3 Studies At ASCO Meeting Extending The Utility Of The Genomic Grade Index For Predicting Response To Chemotherapy In Breast Cancer

IPSOGEN SA (Marseille and New Haven), a cancer profiler that develops and markets molecular diagnostic assays for blood & breast cancers, announced that researchers from the University of Texas MD Anderson Cancer Center (MDACC, Houston, TX) will present the results of two studies on the Genomic Grade index (GGi) at the ASCO Annual Meeting, held in Chicago from May 30 to June 3, 2008. The data indicate that the Genomic Grade index predicts response to chemotherapy in breast cancer.

More: continued here

Filed under: Breast Cancer on May 22nd, 2008